Effect of chitosan chewing gum on reducing serum phosphorus in hemodialysis patients: a multi-center, randomized, double-blind, placebo-controlled trial

Table 3 Salivary phosphorus, serum calcium, serum Ca x P, serum iPHT, serum whole PTH and iFGF23 levels at baseline and week 3

Parameter	Period	HS219		Placebo		Mean difference^a	95% CI	U test
Parameter	Period	n	Mean ± SD	n	Mean ± SD	Mean difference^a	95% CI	U test
Serum phosphorus (mg/dl)	Baseline	35	6.7 ± 1.0	28	6.5 ± 1.3	0.2	-0.5 ~ 0.8	P = 0.677
Serum phosphorus (mg/dl)	Week 3	32	6.4 ± 1.4	28	6.3 ± 1.3	0.1	-0.6 ~ 0.8	P = 0.900
Salivary phosphorus (mg/dl)	Baseline	35	24.0 ± 10.4	28	23.7 ± 8.9	0.2	-4.6 ~ 5.1	P = 0.964
Salivary phosphorus (mg/dl)	Week 3	32	22.3 ± 8.0	28	21.5 ± 9.0	0.8	-3.6 ~ 5.2	P = 0.656
Serum Ca (mg/dl)	Baseline	35	9.3 ± 0.7	28	9.2 ± 0.6	0.2	-0.1 ~ 0.5	P = 0.299
Serum Ca (mg/dl)	Week 3	33	9.4 ± 0.7	28	9.1 ± 0.6	0.2	-0.1 ~ 0.6	P = 0.149
Serum Ca x P (mg²/dl²)	Baseline	35	62.0 ± 10.3	28	59.3 ± 11.1	2.7	-2.8 ~ 8.2	P = 0.490
Serum Ca x P (mg²/dl²)	Week 3	33	59.9 ± 13.9	28	57.2 ± 11.3	2.7	-3.8 ~ 9.1	P = 0.520
iPTH (pg/ml)	Baseline	35	233 ± 148	28	233 ± 156	1	-77 ~ 78	P = 0.760
iPTH (pg/ml)	Week 3	33	207 ± 141	28	251 ± 184	-45	-130 ~ 41	P = 0.511
whole PTH (pg/ml)	Baseline	35	133 ± 89	28	137 ± 97	-4	-51 ~ 44	P = 0.899
whole PTH (pg/ml)	Week 3	33	118 ± 92	28	140 ± 102	-22	-72 ~ 28	P = 0.511
iFGF23 (log₁₀ pg/ml)	Baseline	35	4.1 ± 0.5	28	4.0 ± 0.6	0.1	-0.2 ~ 0.3	P = 0.736
iFGF23 (log₁₀ pg/ml)	Week 3	33	4.0 ± 0.5	28	4.0 ± 0.5	0.0	-0.3 ~ 0.3	P = 0.960

ISSN: 1471-2369